In preparation for an IND submission for Inflammasome ASC Inhibitor IC 100 and a subsequent Phase 1 trial in healthy ... of ...

New insights and emerging scientific trends incorporated into our ACLF development plan, with data readout from 4 clinical trials anticipated by the end of 2025, including data from 3 new clinical ...

Fructose, the most common food sweetener, is widely used in processed sugary beverages, candies, and baked goods. Excessive ...

CVN293 was generally well-tolerated in healthy volunteers for up to 14-days of continuous dosingDose-dependent exposure was ...

MRT-6160, VAV1-directed MGD for immune-mediated conditions In September, Monte Rosa presented preclinical data at the Inflammasome Summit demonstrating that its development candidate MRT-8102, a first ...

Researchers have developed a promising nasal spray therapy targeting neuroinflammation in Alzheimer’s disease, potentially ...

A new therapy may delay Alzheimer's disease progression by years, according to a study by researchers at Texas A&M University ...

“With our potential best-in-class NLRP3 inhibitors, we believe we are well positioned to unlock the vast therapeutic potential of the inflammasome pathway.” Pipeline Updates NLRP3 Portfolio VTX3232 ...

ZyVersa is a clinical-stage biopharmaceutical company with a laser focus on developing first-in-class drugs for diseases that currently have no effective treatments. Its portfolio includes two main ...

Announcing a new publication for Acta Materia Medica journal. Herba Siegesbeckiae (HS) has been traditionally used for ...

ZyVersa Therapeutics (ZVSA) highlights data from an article published in the peer-reviewed International Journal of Nanomedicine titled Small Intestinal Endocrine Cell Derived Exosomal ACE2 Protects ...

Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company pioneering innovative treatments for chronic inflammatory diseases, announced today that it will present promising data on ...